Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Tobias

Gynecologic Oncology Morristown, NJ Medical Doctor

NPI 1508830746 CMS profile 68320

100 Madison Ave, Morristown, NJ 07960

Open in the dashboard

General payments

$11,262

200 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Tobias of Morristown, NJ is reported in the CMS Open Payments database as having received $11,262 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,399 75
2024 General $1,022 56
2023 General $2,586 51
2022 General $13 1
2021 General $2,777 2
2020 General $3,348 7
2019 General $117 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Tobias
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Daniel Tobias were reported at $1,399. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Daniel Tobias Gynecologic Oncology median Middle half National median
2019 $117 $287 $113–$1,548 $163
2020 $3,348 $223 $59–$2,164 $114
2021 $2,777 $193 $68–$1,139 $132
2022 $13 $252 $90–$1,151 $149
2023 $2,586 $281 $102–$1,419 $160
2024 $1,022 $308 $108–$1,502 $164
2025 $1,399 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ethicon Inc. $4,292 3 payments
  2. AbbVie, Inc. $3,166 2 payments
  3. Merck Sharp & Dohme Corporation $980 43 payments
  4. Daiichi Sankyo Inc. $607 38 payments
  5. AstraZeneca Pharmaceuticals LP $439 21 payments
  6. GlaxoSmithKline, LLC. $349 19 payments
  7. Pfizer Inc. $283 16 payments
  8. Mirati Therapeutics, Inc. $153 9 payments
  9. Incyte Corporation $81 5 payments
  10. Foundation Medicine, Inc. $61 2 payments
  11. Other $851 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,442 4 payments
  2. Food and Beverage $3,820 196 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $888 42 payments
  2. ENHERTU $539 34 payments
  3. LYNPARZA Oncology $439 21 payments
  4. JEMPERLI $312 17 payments
  5. ZEJULA $309 17 payments
  6. LYNPARZA Oncology $281 14 payments
  7. TUKYSA $154 9 payments
  8. KRAZATI $153 9 payments
  9. IBRANCE $137 8 payments
  10. ELREXFIO $131 7 payments
  11. Other $1,783 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$150,937

Medicare's payments for the services billed

Medicare patients

442

Average age 74

Services billed

835

442 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Cancer 52%
Arthritis 45%
Osteoporosis 26%
Diabetes 25%
Ischemic heart disease 20%
Depression 17%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $205
$205 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $199
$199 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $101
  • AstraZeneca Pharmaceuticals LP $96
$197 — —
JEMPERLI
  • GlaxoSmithKline, LLC. $61
$61 — —
ZEJULA
  • GlaxoSmithKline, LLC. $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record